Krystal Biotech, Inc.
KRYS
#1848
Rank
$10.648 B
Marketcap
United States
Country
$359.76
Share price
10.00%
Change (1 day)
118.37%
Change (1 year)
Categories
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis…
Key Metrics
Trailing P/E
42.61
Forward P/E
36.18
EPS (TTM)
$7.98
Forward EPS
$9.40
Price / Book
7.40
EV / EBITDA
46.3x
Beta
0.54
Dividend Yield
—
Return on Equity
20.12%
Return on Assets
9.37%
Debt / Equity
0.65
Current Ratio
8.32
Gross Margin
94.64%
Operating Margin
49.00%
Net Profit Margin
54.82%
Free Cash Flow
$151.740M
Charts
Price history and financial performance over time.
Price & Market Cap
Aug 17 – Sep 14
+1.28%
Source: Yahoo Finance daily closes. Market cap uses the closest quarterly shares-outstanding filing for each date.
Revenue & Net Income
Annual · USD
RevenueNet Income
Latest Revenue$389.130M
Latest Net Income$204.831M
Reporting periods3
Source: Yahoo Finance annual income statements. Year is the fiscal-year end. Most recent period may be trailing-twelve-month (TTM) until the next 10-K is filed.
Compare Krystal Biotech, Inc. with competitors
Side-by-side market cap, revenue, and financial comparison.
Latest News
Latest News
KRYS
No recent news available. Set FINNHUB_API_KEY to enable news.
